Afuresertib

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameAfuresertib
Drug Alias NameAfuresertibum阿氟色替阿瑞舍替ASB-183GSK-2110183 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase AKT1 inhibitors
TargetsSerine/threonine-protein kinase AKT1
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursHistiocytosis, Langerhans-Cell +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[10] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesGlaxosmithkline PlcNovartis Pharma Ag
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesDmed Biopharmaceutical Co LtdLaikai Pharmaceutical (Ningbo) Co LtdCambrex Whippany +[7] 
Inactive CompaniesGlaxosmithkline PlcAccentureNovartis Pharma Ag +[4] 
Active IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms, Castration-Resistant +[14] 
Inactive IndicationsHistiocytosis, Langerhans-CellHematologic NeoplasmsMultiple Myeloma +[5] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG